Actavia Life Sciences, Inc. (RASP)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Actavia Life Sciences, Inc. (RASP) with AI Score 44/100 (Weak). Actavia Life Sciences, Inc. is a biotechnology company focused on developing therapeutics for leukemia and lymphoma. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Actavia Life Sciences, Inc. (RASP) Healthcare & Pipeline Overview
Actavia Life Sciences, Inc., a biotechnology firm, focuses on developing therapeutics for leukemia and lymphoma, particularly small molecule drug candidates for acute myeloid leukemia. Operating in the competitive biotechnology sector, the company navigates the high-risk, high-reward landscape of drug development with a focus on hematological malignancies.
Investment Thesis
Actavia Life Sciences, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on developing therapeutics for leukemia and lymphoma, particularly AML, addresses a significant unmet medical need. However, as of 2026-03-16, the company's market capitalization is $0.00B, and it operates with a single employee, indicating an early stage of development. A negative P/E ratio of -0.07 suggests the company is not currently profitable. The company's success hinges on its ability to advance its drug candidates through preclinical and clinical development, secure regulatory approvals, and ultimately commercialize its therapies. Investors should carefully consider the inherent risks associated with biotechnology investments, including the potential for clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.00B, indicating a micro-cap company.
- P/E ratio of -0.07, reflecting current lack of profitability.
- Beta of -64.36, suggesting an inverse correlation with the market, but should be interpreted with caution due to the company's size and stage.
- Focus on developing therapeutics for leukemia and lymphoma, addressing a significant unmet medical need.
- Operates with a single employee, indicating a very early stage of development and high reliance on external resources.
Competitors & Peers
Strengths
- Focus on a specific therapeutic area (leukemia and lymphoma).
- Development of small molecule drug candidates.
- Potential for novel therapies to address unmet medical needs.
- Location in New York City, providing access to talent and resources.
Weaknesses
- Early stage of development with limited resources (one employee).
- Lack of revenue and profitability.
- High dependence on external funding.
- Significant regulatory and clinical development risks.
Catalysts
- Upcoming: Announcement of preclinical data for AML drug candidates.
- Upcoming: Initiation of Phase 1 clinical trial for lead drug candidate.
- Ongoing: Pursuit of strategic partnerships and collaborations.
- Ongoing: Efforts to secure additional funding and investment.
- Ongoing: Research and development activities to expand pipeline.
Risks
- Potential: Clinical trial failures and setbacks.
- Potential: Regulatory hurdles and delays.
- Potential: Competition from established pharmaceutical companies.
- Potential: Inability to secure sufficient funding.
- Ongoing: Limited resources and operational capacity due to small size.
Growth Opportunities
- Advancement of AML drug candidates: Actavia's primary growth opportunity lies in the successful development and commercialization of its small molecule drug candidates targeting acute myeloid leukemia. The global AML market is projected to reach billions of dollars, offering significant revenue potential for Actavia if its therapies prove effective and safe. Timeline: Ongoing, with preclinical and clinical milestones to be achieved.
- Expansion into other hematological malignancies: Actavia could expand its pipeline to include therapeutics for other hematological malignancies beyond leukemia and lymphoma. This would broaden its addressable market and diversify its product portfolio. Timeline: Potential expansion within the next 3-5 years, contingent on successful advancement of current pipeline.
- Strategic partnerships and collaborations: Actavia could pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its drug candidates. This would provide access to additional funding, expertise, and resources. Timeline: Ongoing, with potential partnerships to be formed as pipeline progresses.
- Out-licensing of drug candidates: Actavia could out-license its drug candidates to other companies for further development and commercialization. This would generate upfront and milestone payments, as well as royalties on future sales. Timeline: Potential out-licensing opportunities as pipeline progresses and clinical data becomes available.
- Acquisition by a larger pharmaceutical company: Actavia could be acquired by a larger pharmaceutical company seeking to expand its oncology pipeline. This would provide a significant return on investment for Actavia's shareholders. Timeline: Potential acquisition within the next 5-7 years, contingent on successful pipeline development and clinical data.
Opportunities
- Advancement of drug candidates through clinical trials.
- Strategic partnerships and collaborations with larger pharmaceutical companies.
- Expansion into other hematological malignancies.
- Out-licensing of drug candidates.
Threats
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from established pharmaceutical companies.
- Inability to secure sufficient funding.
Competitive Advantages
- Intellectual property protection (patents) on novel drug candidates.
- Proprietary knowledge and expertise in drug discovery and development.
- Potential for orphan drug designation, providing market exclusivity.
- First-mover advantage in developing novel therapies for specific subtypes of leukemia and lymphoma.
About RASP
Founded in 2013 and headquartered in New York City, Actavia Life Sciences, Inc. is a biotechnology company dedicated to the discovery and development of novel therapeutics for the treatment of leukemia and lymphoma. The company's primary focus is on developing small molecule drug candidates that target acute myeloid leukemia (AML), a particularly aggressive form of blood cancer. Actavia's research and development efforts are centered on identifying and validating promising drug targets and advancing preclinical candidates towards clinical trials. As a biotechnology company, Actavia operates within a complex and highly regulated environment, requiring significant investment in research, development, and clinical testing to bring its therapies to market. The company's success depends on its ability to successfully navigate the drug development process, secure regulatory approvals, and ultimately commercialize its products.
What They Do
- Develops therapeutics for the treatment of leukemia and lymphoma diseases.
- Focuses on small molecule drug candidates.
- Targets acute myeloid leukemia (AML).
- Conducts research and development activities.
- Seeks to identify and validate promising drug targets.
- Advances preclinical candidates towards clinical trials.
Business Model
- Develops and patents novel therapeutic compounds.
- Conducts preclinical and clinical trials to evaluate the safety and efficacy of its drug candidates.
- Seeks regulatory approval from agencies such as the FDA.
- May out-license or partner with larger pharmaceutical companies for commercialization.
Industry Context
Actavia Life Sciences, Inc. operates within the biotechnology industry, a sector characterized by intense competition, high research and development costs, and significant regulatory oversight. The market for leukemia and lymphoma therapeutics is substantial, driven by the prevalence of these diseases and the ongoing need for more effective treatments. Actavia competes with both established pharmaceutical companies and other biotechnology firms in the development of novel therapies. The company's success depends on its ability to differentiate its drug candidates, secure intellectual property protection, and navigate the complex regulatory landscape.
Key Customers
- Patients suffering from leukemia and lymphoma.
- Healthcare providers who treat these patients.
- Pharmaceutical companies interested in licensing or acquiring novel therapeutics.
Financials
Chart & Info
Actavia Life Sciences, Inc. (RASP) stock price: Price data unavailable
Latest News
No recent news available for RASP.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RASP.
Price Targets
Wall Street price target analysis for RASP.
MoonshotScore
What does this score mean?
The MoonshotScore rates RASP's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Keeren Shah
CEO
Keeren Shah is the CEO of Actavia Life Sciences, Inc. Details regarding Keeren Shah's prior experience and educational background are not available in the provided data. As the leader of a biotechnology company focused on developing therapeutics for leukemia and lymphoma, Keeren Shah's expertise likely includes areas such as drug development, oncology, and business strategy. The success of Actavia Life Sciences depends heavily on Keeren Shah's ability to navigate the complex biotechnology landscape and secure funding.
Track Record: As of 2026-03-16, Actavia Life Sciences, Inc. is in an early stage of development, with a market capitalization of $0.00B and only one employee. Key milestones under Keeren Shah's leadership would include advancing drug candidates through preclinical and clinical development, securing regulatory approvals, and establishing strategic partnerships. However, specific achievements and strategic decisions are not detailed in the provided data.
RASP OTC Market Information
The OTC Other tier, where Actavia Life Sciences trades, represents the lowest tier of the OTC market. Unlike stocks listed on major exchanges like the NYSE or NASDAQ, companies on the OTC Other tier often have limited financial disclosure requirements and may not meet minimum listing standards. This tier is generally considered to be the most speculative and carries the highest risk due to the potential for limited information and regulatory oversight. Companies in this tier may be newly formed, financially distressed, or have chosen not to meet the stricter requirements of higher-tier exchanges. Investing in OTC Other stocks requires a high degree of due diligence and risk tolerance.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation and fraud.
- Higher risk of company failure or delisting.
- Limited regulatory oversight and investor protection.
- Verify the company's registration and legal status.
- Attempt to obtain audited financial statements.
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with the company's industry and operations.
- Consult with a qualified financial advisor.
- Be prepared to lose your entire investment.
- Company has been in operation since 2013.
- Focus on developing therapeutics for a specific disease area (leukemia and lymphoma).
- Headquartered in New York City.
- Presence of a CEO (Keeren Shah).
RASP Healthcare Stock FAQ
What does Actavia Life Sciences, Inc. do?
Actavia Life Sciences, Inc. is a biotechnology company focused on the development of therapeutics for leukemia and lymphoma, with a particular emphasis on acute myeloid leukemia (AML). The company's business model revolves around identifying promising drug targets, developing small molecule drug candidates, and advancing them through preclinical and clinical development. Actavia aims to address the unmet medical need for more effective treatments for these hematological malignancies.
What do analysts say about RASP stock?
As of 2026-03-16, there is no available analyst coverage or consensus for Actavia Life Sciences, Inc. (RASP). The company's micro-cap status and OTC listing likely contribute to the lack of analyst attention. Investors should conduct their own independent research and due diligence before making any investment decisions. Key valuation metrics, such as revenue projections and earnings estimates, are not currently available.
What are the main risks for RASP?
The main risks for Actavia Life Sciences, Inc. include clinical trial failures, regulatory hurdles, competition from established pharmaceutical companies, and the inability to secure sufficient funding. As a small biotechnology company operating on the OTC market, Actavia faces significant challenges in advancing its drug candidates through the development process. The company's limited resources and operational capacity also pose risks to its ability to execute its business plan.
What is Actavia Life Sciences, Inc.'s drug pipeline status?
Actavia Life Sciences, Inc.'s drug pipeline focuses on therapeutics for leukemia and lymphoma, particularly small molecule drug candidates targeting acute myeloid leukemia (AML). As of 2026-03-16, the specific stages of development for each drug candidate are not detailed in the provided data. Investors should seek additional information regarding the company's preclinical and clinical development programs to assess the potential for future catalysts.
How does Actavia Life Sciences, Inc. plan to navigate the regulatory landscape for drug approval?
Given Actavia Life Sciences, Inc.'s focus on developing therapeutics for leukemia and lymphoma, the company will need to navigate a complex regulatory landscape to gain approval for its drug candidates. This includes conducting rigorous preclinical and clinical trials to demonstrate safety and efficacy, as well as complying with regulations set forth by agencies such as the FDA. The company may also seek orphan drug designation for its therapies, which can provide market exclusivity and other benefits.
What are the key factors to evaluate for RASP?
Actavia Life Sciences, Inc. (RASP) currently holds an AI score of 44/100, indicating low score. Key strength: Focus on a specific therapeutic area (leukemia and lymphoma).. Primary risk to monitor: Potential: Clinical trial failures and setbacks.. This is not financial advice.
How frequently does RASP data refresh on this page?
RASP prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven RASP's recent stock price performance?
Recent price movement in Actavia Life Sciences, Inc. (RASP) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Focus on a specific therapeutic area (leukemia and lymphoma).. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available for Actavia Life Sciences, Inc.
- OTC market carries higher risks than major exchanges.
- Financial data is limited and may not be up-to-date.